[7].Sunitha Shyam Sunde, Umesh C. Sharma and Saraswati Pokharel. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy, ...
In the interview, Smaglo detailed ongoing research with RAS inhibitors in pancreatic cancer, explained how the development of these agents has evolved, and highlighted additional work underway in the pancreatic cancer space. Smaglo is an associate professor in the Department of Gastrointestinal Medical ...
RAS oncogenes are frequently activated by mutations in pancreatic and lung cancer, where they appear to act as driving mutations. This study examines the activity of a series of novel direct RAS inhibitors with a predicted unique interaction region. We have used in silico library screening ...
10. Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).11. Ostrem, Jonathan M. L. and Shokat, Kevan M. Direct small-molecule inhibitors of KRAS_ from structural insights to mechanism-based design. Nature Reviews ...
Alberts SR. K-ras inhibitors and pancreatic cancer. In: Lowy AM, Leach SD, Philip PA, eds. Pancreatic Cancer: M.D. Anderson Solid Tumor Oncology Series. New York: Springer; 2008:601Y607.Alberts SR. K-ras inhibitors and pancreatic cancer. Pancreatic Cancer M. D. Anderson Solid Tumor ...
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(...
Though KRAS G12C is a prominent mutation seen in lung cancer, certain malignancies such as pancreatic cancer most commonly have the G12D mutation in the KRAS gene. Therefore, there is a need for KRAS inhibitors that can treat other cancer types. ...
法尼基转移酶抑制剂(farnesyltransferase inhibitors,FTIs)开发的失败是由于一个观念的错误,即认为这四种RAS蛋白在功能上是一样的。随着研究的深入,人们逐渐意识到,不同的RAS蛋白在肿瘤中发挥着不同的作用。因此,研究人员将重点转移到了最常见的突变形式KRAS及其主要的剪切突变体KRAS4B上。
RAS mutations, such as KRASG12Dand KRASG12V, in difficult to treat cancers, including pancreatic, colorectal, lung and endometrial cancer types. KRAS inhibitors have been developed to target the KRASG12Cmutation, but these therapies are limited to only around ten percent of KRAS-driven cancers...
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer July 11, 2024 Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust ...